| Literature DB >> 35390768 |
Richard T Hoppe1, Ranjana H Advani1, Weiyun Z Ai2, Richard F Ambinder3, Philippe Armand4, Celeste M Bello5, Cecil M Benitez6, Weina Chen7, Bouthaina Dabaja8, Megan E Daly9, Leo I Gordon10, Neil Hansen11, Alex F Herrera12, Ephraim P Hochberg13, Patrick B Johnston14, Mark S Kaminski15, Christopher R Kelsey16, Vaishalee P Kenkre17, Nadia Khan18, Ryan C Lynch19, Kami Maddocks20, Jonathan McConathy21, Monika Metzger22, David Morgan23, Carolyn Mulroney24, Sheeja T Pullarkat6, Rachel Rabinovitch25, Karen C Rosenspire26, Stuart Seropian27, Randa Tao28, Pallawi Torka29, Jane N Winter10, Joachim Yahalom30, Joanna C Yang31, Jennifer L Burns32, Mallory Campbell32, Hema Sundar32.
Abstract
Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte-predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment options that overriding treatment considerations often relate to long-term toxicity. These NCCN Guidelines Insights discuss the recent updates to the NCCN Guidelines for HL focusing on (1) radiation therapy dose constraints in the management of patients with HL, and (2) the management of advanced-stage and relapsed or refractory cHL.Entities:
Mesh：
Year: 2022 PMID： 35390768 DOI： 10.6004/jnccn.2022.0021
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908